Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Aclaris Therapeutics Inc (NASDAQ:ACRS) has announced leadership changes as the company undertakes a strategic review of its business.
Aclaris and Douglas Manion have reached a mutual agreement for him to immediately step down from his roles as Chief Executive Officer, President, and Board Member at Aclaris.
In connection with his departure, the Board has appointed Neal Walker, Aclaris’ Chairman of the Board of Directors, as Interim Chief Executive Officer.
Dr. Walker is a co-founder of Aclaris, has been a member of the Board of Directors since its inception, and previously served as Aclaris’ Chief Executive Officer until 2022.
Concurrently, Aclaris also announced that it is conducting a strategic review.
On a preliminary unaudited basis, as of Dec. 31, 2023, Aclaris’ aggregate cash, cash equivalents, and marketable securities were approximately $182 million.
Aclaris also reiterates the following business plans:
Price Action: ACRS shares were up 25% at $1.16 at last check Tuesday.
Also Read: Inflammatory Disease Focused Aclaris Therapeutics Reduces Staff After Failed Psoriatic Arthritis Study.
Photo: Unsplash
Posted In: ACRS